Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Probiotics Can Increase Effectiveness Of Some Antibiotic Therapies For Bacterial Vaginosis
Antimicrobial treatments for bacterial vaginosis (BV) are effective, but taking lactobacillus tablets alongside metronidazole antibiotic therapy increases effectiveness over taking this antibiotic alone, according to a Cochrane Systematic Review. The researchers also concluded that intravaginal lactobacillus was as effective as oral metronidazole, although they did note unexplained drop-outs from the trials.

What Is A PET Scan? How Does A PET Scan Work?
A PET scan uses radiation, or nuclear medicine imaging, to produce 3-dimensional, color images of the functional processes within the human body. PET stands for positron emission tomography. The machine detects pairs of gamma rays which are emitted indirectly by a tracer (positron-emitting radionuclide) which is placed in the body on a biologically active molecule. The images are reconstructed by computer analysis. Modern machines often use a CT X-ray scan which is performed on the patient at the same time in the same machine.
News of the day
Policymakers, Experts, Public Agree: Physical Activity Plan Needed
Dozens of the nation"s leading organizations in health care, science, medicine and public health are meeting in Washington, D.C., this week with one goal in mind: to develop a national physical activity plan that will make America healthier. Congressional leaders and members of the public both agree that emphasizing disease prevention measures, such as increasing physical activity, is essential to combating chronic diseases, which account for 70 percent of all deaths in the U.S., according to the Centers for Disease Control and Prevention.
Nutrition

Galapagos Initiates Clinical Studies With GLPG0187, A Candidate Drug For Bone Metastasis

Galapagos NV (Euronext: GLPG) announced that it has initiated Phase I clinical development of its integrin receptor antagonist (IRA), GLPG0187. This is the second small molecule therapeutic from Galapagos" internal drug discovery program to enter the clinic in 2009. Candidate drug GLPG0187 could offer a promising new therapeutic approach for treating cancer patients. Initial development will focus on bone metastases from prostate and breast cancer. Strong anti-cancer therapeutic profile in pre-clinical models GLPG0187 offers a potentially highly competitive therapeutic profile compared to currently available agents to treat bone metastasis, a severe aspect of many cancers. GLPG0187 blocks five integrin receptors known to be present in many metastatic cancers, affording a unique anti-integrin profile. In animal studies, oral administration of GLPG0187 as a single agent has been shown to inhibit multiple processes involved in the spread and growth of tumors and the destruction of bone. In these models, GLPG0187 also provided additive benefits to the bone protective action reported for currently used treatments(1). Based on the pre-clinical safety and efficacy data, Galapagos has been granted permission to initiate a first-in-human Phase I study to evaluate this compound"s safety, tolerability and pharmacokinetic properties, which will aid in evaluating its further development for the treatment of bone metastases. "We are pleased to announce the transition of GLPG0187 into clinical development," said Onno van de Stolpe, CEO of Galapagos. "This candidate drug has been shown to affect several steps in cancer disease progression in pre-clinical studies - suggesting that it may slow down the growth of existing bone metastasis as well as protect organs from invading cancer cells." Details of the Phase I clinical trial The primary endpoints of this first-in-human trial will be to determine the safety, tolerability and pharmacokinetics of the candidate drug GLPG0187 as well as the evaluation of biomarkers to aid in the design of later trials. The double-blind, single ascending dose study will be conducted in 18 healthy human volunteers in Belgium over the coming months. About Galapagos Galapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery and development company with small molecule programs in bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases. It has established risk sharing alliances with GSK, Janssen Pharmaceutica, Eli Lilly and Merck. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. Galapagos currently employs 490 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: http://www.glpg.com. Galapagos


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009